Spruce Biosciences, Inc. (SPRB) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.02
↓-17% vs avg
5yr avg: 1.23
30Y Low0.6·High7.4
ROE
↓
-109.2%
↑-52% vs avg
5yr avg: -72.0%
30Y Low-109%·High-32%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SPRB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Spruce Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $78M | $67M | $17M | $110M | $50M | $203M | $1.1B | — | — |
| Enterprise Value | $29M | $19M | $-19090014 | $18M | $32M | $167M | $952M | — | — |
| P/E Ratio → | -1.11 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 3.44 | 10.90 | — | — | — | — | — |
| P/B Ratio | 1.02 | 1.57 | 0.59 | 1.44 | 0.73 | 1.82 | 7.38 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SPRB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | -3.89 | 1.81 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
SPRB Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from -515.3% to -1143.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -109.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | — | — | — | — | — |
| Operating Margin | — | — | -1143.4% | -515.3% | — | — | — | — | — |
| Net Profit Margin | — | — | -1079.9% | -475.0% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -109.2% | -109.2% | -100.7% | -66.1% | -51.4% | -32.4% | -49.7% | — | — |
| ROA | -79.3% | -79.3% | -71.1% | -50.5% | -43.5% | -29.2% | -35.3% | -279.6% | -206.5% |
| ROIC | — | — | — | -222.2% | -56.5% | -85.5% | — | — | — |
| ROCE | -100.2% | -100.2% | -102.6% | -68.1% | -49.6% | -31.1% | -38.3% | -1066.0% | -481.7% |
SPRB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $49M exceeds total debt of $736000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.10 | 0.06 | 0.09 | 0.06 | 0.04 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.13 | -1.25 | -1.20 | -0.27 | -0.33 | -1.01 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -405.70 | -405.70 | -171.76 | -98.21 | -108.95 | -121.59 | -91.07 | -200.35 | — |
Net cash position: cash ($49M) exceeds total debt ($736000)
SPRB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Spruce Biosciences, Inc.'s current ratio of 5.17x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.18x to 5.17x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.17 | 5.17 | 2.90 | 4.18 | 6.72 | 10.36 | 16.43 | 1.08 | 1.76 |
| Quick Ratio | 5.17 | 5.17 | 2.90 | 4.18 | 6.72 | 10.36 | 16.43 | 1.08 | 1.76 |
| Cash Ratio | 4.85 | 4.85 | 2.54 | 3.94 | 6.35 | 10.03 | 16.10 | 0.91 | 1.52 |
| Asset Turnover | — | — | 0.11 | 0.10 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
SPRB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Spruce Biosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $766598 | $536444 | $500633 | $611705 | $607397 | $604770 | $578853 | $19875 |
Peer Comparison
Compare SPRB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SPRBYou | $78M | -1.1 | — | — | — | — | -109.2% | — | — |
 CORT | $5B | 62.3 | 114.9 | 38.7 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
 XNCR | $903M | -9.9 | — | — | 91.6% | -141.4% | -14.0% | -16.3% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 ACRS | $586M | -9.2 | — | — | 73.3% | -975.9% | -50.2% | -53.5% | — |
 HRMY | $2B | 11.6 | 5.6 | 5.2 | 77.2% | 24.0% | 20.8% | 42.0% | 1.0 |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 VNDA | $378M | -1.7 | — | — | 94.0% | -70.0% | -50.9% | -32.2% | — |
 IQV | $30B | 22.8 | 13.0 | 14.8 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See SPRB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SPRB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SPRB vs CORT
Side-by-side business, growth, and profitability comparison vs Corcept Therapeutics Incorporated.
Start ComparisonSPRB — Frequently Asked Questions
Quick answers to the most common questions about buying SPRB stock.
What is Spruce Biosciences, Inc.'s P/E ratio?
Spruce Biosciences, Inc.'s current P/E ratio is -1.1x. This places it at the 50th percentile of its historical range.
What is Spruce Biosciences, Inc.'s ROE?
Spruce Biosciences, Inc.'s return on equity (ROE) is -109.2%. The historical average is -68.3%.
Is SPRB stock overvalued?
Based on historical data, Spruce Biosciences, Inc. is trading at a P/E of -1.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.